Related Experiment Video
Updated: Jun 22, 2026

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes
Published on: December 19, 2020
Quadrivalent meningococcal conjugate vaccines
David Pace1, Andrew J Pollard, Nancy E Messonier
1Department of Paediatrics, Mater Dei Hospital, Tal-Qroqq, Msida, MSD 2090, Malta. dpace@mail.global.net.mt
Abstract:
Neisseria meningitidis is an important cause of bacterial meningitis and septicaemia with most disease caused by meningococci bearing serogroups A, B, C, Y and W-135 polysaccharides. Monovalent serogroup C conjugate vaccines have become established in the immunisation programmes in many countries and the first quadrivalent meningococcal vaccine, containing the polysaccharides from 4 of the serogroups A, C, Y and W-135 meningococci conjugated to a protein carrier was licensed in the US in 2005. This vaccine and others in development offer the potential to broaden population protection against meningococcal disease.
Related Concept Videos
Bacterial Meningitis
Cryptococcal Meningitis
Bacterial Meningitis I: Introduction
Vaccines
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Bacterial Meningitis II: Pathophysiology

